Canopy Growth Corp

Canopy Growth Corp(CGC)の株式分析

$0.684

+0.017 (+2.42%)終値時点

Loading chart…
高値
0.695
始値
0.673
出来高加重平均価格
0.68
出来高
1.31M
時価総額
508.24M
安値
0.661
売買代金
889.52K
EV/EBITDA(TTM)
-5.81

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany.

www.canopygrowth.com

AI分析 of Canopy Growth Corp (CGC)

売り

Canopy Growth Corp is not a good buy right now due to its significant financial losses and negative sentiment in the market. The current price is $0.6758, with a 5-day change of -5.22% and a 1-year change of -48.80%. Additionally, the RSI is at a very low 22.15, indicating oversold conditions but also reflecting the stock's ongoing struggles. The main risk is the company's net income loss of approximately $157 million in Q4 2026, which raises concerns about its sustainability and future profitability.

バリュエーション指標

Canopy Growth Corp(CGC)の現在の予想PERは20.37で、5年平均は-1.06です。

予想PER

大幅な割高
5年平均 P/E
-1.06
現在のP/E
20.37
割高
8.96
割安
-11.08

予想EV/EBITDA

適正
5年平均 EV/EBITDA
-274.82
現在のEV/EBITDA
-5.81
割高
449.53
割安
-999.17

予想PSR

適正
5年平均 P/S
2.87
現在のP/S
0.83
割高
5.08
割安
0.67

Alphio AI による CGC の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%CGC

$1.78

シナリオ価格

基

基本

基本 · 50%CGC

$1.69

シナリオ価格

弱

弱気

弱気 · 25%CGC

$1.41

シナリオ価格

イベントタイムライン

2026-10-26 (ET)

08:00:00

Canopy Growth Shareholders Approve Multiple Resolutions

2026-09-28 (ET)

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

08:00:00

Canopy Growth Appoints Sebastian Blote as Country Manager for Germany

2026-09-22 (ET)

08:00:00

Canopy Growth Supplies Medical Cannabis Flowers to the UK

2026-09-08 (ET)

08:00:00

Canopy Growth Expands Medical Cannabis Portfolio in Australia

ニュース

CGC のよくある質問 — Alphio AI が回答

Canopy Growth Corporation is a cannabis company, which produces, distributes, and sells a diverse range of cannabis and cannabis-related products for both adult-use and medical purposes. The Company brands include tweed, DOJA, LivRelief Infused, Deep Space, Ace Valley, 7ACRES, Vert, Twd, Wana, Hiway and Canopy Medical. The LivRelief Infused is transdermal creams contain a delivery system designed to penetrate a range of cannabidiol (CBD) and tetrahydrocannabinol (THC). The Deep Space offers beverages and gummies, containing the THC potency available in the Canadian market. The Ace Valley is a cannabis brand focused on ready-to-enjoy beverages. The 7ACRES offers products that are crafted by cannabis enthusiasts. The Wana gummies are created with a handcrafted recipe made with pectin, not gelatin, creating a gluten-free shelf-stable recipe that doesn’t melt. Its Canopy Medical is a pharmaceutical manufacturer for the production, import and release of medical cannabis products in Germany. It operates in the Healthcare sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Canopy Growth Corp is not a good buy right now due to its significant financial losses and negative sentiment in the market. The current price is $0.6758, with a 5-day change of -5.22% and a 1-year change of -48.80%. Additionally, the RSI is at a very low 22.15, indicating oversold conditions but also reflecting the stock's ongoing struggles. The main risk is the company's net income loss of approximately $157 million in Q4 2026, which raises concerns about its sustainability and future profitability.

コミュニティ

もっと見る ↗
0xSkewfalcon2026/9/27

As mid-term elections approach and marijuana legalization comes up for debate again, $CGC is a chart worth watching. A large triangle pattern is close to a breakout. If it can reclaim its 50 DMA, there could be upside ahead 📈🌿 $1+ looks fairly likely again in the near future.

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める